Summary by Moomoo AI
Merck & Co., Inc. (Merck) reported a robust financial performance in the second quarter of 2024, with worldwide sales reaching $16.1 billion, a 7% increase compared to the same quarter in 2023. Excluding the impact of foreign exchange, sales grew by 11%. The U.S. market saw a 12% increase in sales, while international sales rose by 3%. The company's growth was primarily driven by higher sales in the oncology franchise, particularly Keytruda and Welireg, as well as increased sales in the vaccines franchise, including Gardasil/Gardasil 9 and Vaxneuvance. However, sales in the diabetes franchise, including Januvia and Janumet, declined due to competitive pressures and pricing challenges. Merck's business development activities included the acquisition of the aqua business of Elanco for $1.3 billion, expanding its Animal Health...Show More
